Laura Marks
LightNews LightNews
lauramarks.bsky.social
Laura Marks
@lauramarks.bsky.social
620 followers 1.8K following 12 posts
ID physician scientist interested in improving care for individuals with SUD-associated infections #IDSky
Posts Replies Media Videos
lauramarks.bsky.social
Hot off the press! Our experience in providing HCV meds in-hand to postpartum women at discharge from hospital admissions for labor and delivery.

Meds to beds = higher HCV treatment completion than a traditional linkage to outpatient care-based approach.

journals.lww.com/ogopen/fullt...
journals.lww.com
September 11, 2025 at 10:40 PM
lauramarks.bsky.social
@madelinemc5.bsky.social and I are excited to share that our HCV rapid start program at WashU ID has delivered over 200 courses of HCV meds to the bedside for inpatients at BJH! This allows people to start HCV rx at discharge, just like they would for any other new med prescribed on discharge.
June 16, 2025 at 11:06 PM
Reposted by Laura Marks
paulsaxmd.bsky.social
With the publication of PURPOSE 2 for PrEP in @nejm.org, and the stellar results, I wonder what’s going to happen once it gets approved for this indication. Should be interesting, to say the least! blogs.jwatch.org/hiv-id-obser...
Who's Going to Get Lenacapavir for HIV Prevention?
At the International AIDS Conference this past summer, Dr. Linda-Gail Bekker brought down the house presenting the results of the PURPOSE 1 trial of twice-yearly injectable lenacapavir for prevention ...
blogs.jwatch.org
December 9, 2024 at 9:27 AM
Reposted by Laura Marks
cidjournal.bsky.social
Re-infection and resistance associated substitutions following a minimal monitoring approach for HCV treatment in MINMON trial

✅ Just Accepted
#IDsky
Reinfection and resistance associated substitutions following a minimal monitoring approach for HCV treatment in MINMON trial
Simplified approaches to HCV treatment delivery are needed to meet elimination goals. However, the impact of low-touch strategies on individuals at higher risk due to treatment failure or reinfection is unknown. We estimated HCV reinfection rates, and the impact of resistance associated substitutions (RASs) on response in the ACTG A5360 (MINMON) trial.
buff.ly
December 22, 2024 at 7:58 PM
Reposted by Laura Marks
ofidjournal.bsky.social
Long-term 4CMenB vaccine effectiveness against gonococcal infection at four years post program implementation: observational case-control study

✅ Just Accepted
#IDSKy
Long-term 4CMenB vaccine effectiveness against gonococcal infection at four years post program implementation: observational case-control study
A four-component meningococcal B (4CMenB) vaccine program was introduced in adolescents in 2019 in South Australia. We aimed to evaluate long-term vaccine effectiveness (VE) and impact (VI) on gonococcal infection four years after implementation of the program.
buff.ly
December 19, 2024 at 10:11 PM
Reposted by Laura Marks
madhupai.bsky.social
A superb collection of free, practical guides and hands-on resources for authors looking to improve their scientific publishing skillset by @plos.bsky.social

plos.org/resources/wr...
December 2, 2024 at 3:07 PM
lauramarks.bsky.social
This is such important data! So glad to see it out in print! Being able to offer our pregnant patients biktarvy has been such a game-changer 🥰
December 14, 2024 at 11:19 PM
lauramarks.bsky.social
Such a treat to open my OFID inbox this morning and see so many amazing papers by teams from across the globe on care of PWUD with infections.

Hoping potential reviewers also feel the same way 😆🤩😆. Reviewer invites for all our #IDCircus friends forthcoming.
December 13, 2024 at 5:20 PM